COLL Q2 2018 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$73M+1952.3% YoY

Gross Profit

$26M35.9% margin

Operating Income

-$7M-10.0% margin

Net Income

-$13M-17.9% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+14.6%

Cash Flow

Operating Cash Flow

$56M

Free Cash Flow

$55M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$673M

Total Liabilities

$591M

Stockholders' Equity

$83M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$4M	+1952.3%
Gross Profit	$26M	$3M	+779.1%
Operating Income	-$7M	-$21M	+65.7%
Net Income	-$13M	-$21M	+38.2%

Revenue Segments

Nucynta

$55M75%

Xtampza

$18M25%